Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2025-01-10 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房《公司章程》（2025年1月修订）
Governance Information Classification · 100% confidence The document is titled "益丰大药房连锁股份有限公司 公司章程" which translates to "Yifeng Pharmacy Chain Co., Ltd. Articles of Association" or "Company Bylaws." The content includes detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting systems, profit distribution, auditing, and procedures for shareholder meetings. It is a comprehensive governance document outlining the internal rules, board structure, shareholder meetings, and management responsibilities. There is no indication that this is an annual report, financial statement, or any other type of financial or regulatory filing. Instead, it is a governance document that defines the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2025-01-10 Chinese
益丰药房关于使用闲置募集资金委托理财到期赎回并继续委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the redemption and reinvestment of idle raised funds into financial products. It details the amounts, types of financial products, risk analysis, and board approval. It does not contain financial statements or comprehensive financial data but rather informs about the company's financing activities related to raised funds. The document length is 2839 characters, which is relatively short and focused on a specific financing update. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2025-01-07 Chinese
益丰药房高级管理人员集中竞价减持股份结果公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share reduction (share sale) by a senior management person, specifically a vice president named Zhang Chaoxu. It details the number of shares held before and after the sale, the percentage of total shares, the method of sale (centralized bidding), and confirms that the reduction plan has been completed. There is no financial report, earnings data, or regulatory certification. The content fits the definition of a Transaction in Own Shares (POS) filing, which reports company insiders or management selling their own shares. The document length is short and focused solely on the share reduction transaction by a senior executive, matching the POS category perfectly.
2025-01-03 Chinese
益丰药房关于可转债转股结果暨股份变动公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Yifeng Pharmacy Chain Co., Ltd. regarding the results of convertible bond conversions and related changes in share capital. It provides detailed data on the amount of convertible bonds converted into shares, the remaining unconverted bonds, and the resulting changes in share capital as of specific dates. The document includes regulatory approval references and trading information for the convertible bonds. It is not a full financial report, earnings release, or management discussion, but a specific update on capital structure changes due to convertible bond conversions. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused on convertible bond conversion results and share capital changes, not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2025-01-03 Chinese
益丰药房关于使用闲置募集资金委托理财到期赎回并继续委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 益丰大药房连锁股份有限公司 regarding the redemption and continued investment of idle raised funds into financial products. It details the amounts, types of structured deposits, investment purposes, risk analysis, and board approval. The document is relatively short (3314 characters) and focuses on a specific financing activity related to the use of raised funds, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly/yearly results. It is not a report publication announcement since it contains substantive information about the transaction itself. The content fits best under Capital/Financing Update (CAP) as it updates on the company's use of raised capital for financial investments.
2024-12-26 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2024年第四次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the procedures, attendance, and voting results of a company's 2024 fourth extraordinary general meeting (临时股东会). It details the verification of meeting notices, attendance, voting methods, and results, and concludes on the legality of the meeting process. It does not contain financial statements or financial performance data, nor is it a report of voting results alone. It is a legal opinion related to a shareholders meeting, which is a specialized legal document rather than a general regulatory filing or announcement. Given the nature of the document as a legal opinion on the shareholders meeting, it best fits under Regulatory Filings (RNS) as it does not match other more specific categories such as Declaration of Voting Results (DVA) or Proxy Solicitation (PSI). The document length is under 5,000 characters and is a standalone legal opinion letter, not a full report or announcement of a report publication.
2024-12-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.